期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

应正确认识靶向药物在肺动脉高压治疗中的地位 被引量：7

原文传递
导出
摘要 尽管有关肺动脉高压的发病机制目前尚不完全清楚，但近20年来的研究表明：多种致病因素作用于肺血管，引起肺血管损伤，造成血管收缩或增殖与血管舒张或抗增殖之间的细胞因子失衡，肺小动脉重塑，肺小动脉闭塞，最后导致肺动脉高压。目前已经明确内皮素、一氧化氮和前列环素的失衡是参与肺动脉高压形成的重要原因，也已经针对其合成和代谢途径开发出治疗肺动脉高压的靶向药物，还有一些针对肺动脉高压其他发病途径的药物也在研发之中。这些药物的应用旨在纠正肺血管细胞因子的失衡，阻抑重塑，从而延迟或逆转肺小动脉的闭塞，降低肺血管阻力。靶向药物与原有的传统治疗药物联合应用，极大丰富了肺动脉高压药物治疗手段，使肺动脉高压患者运动耐量、生活质量和生存率得到明显改善。
作者 熊长明
机构地区 中国医学科学院阜外心血管病医院肺血管病诊治中心
出处 《中华医学杂志》 CAS CSCD 北大核心 2012年第22期1515-1516,共2页 National Medical Journal of China
关键词 肺动脉高压形成 靶向药物 高压治疗 细胞因子失衡 肺血管损伤 发病机制 动脉闭塞 联合应用
分类号 R543.2 [医药卫生—心血管疾病]
  • 相关文献

参考文献9

  • 1Galie N, Manes A, Negro L, et al. A recta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J, 2009, 30: 394-403.
  • 2McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation, 2002, 106 : 1477-1482.
  • 3Barst RJ. Recent advances in the treatment of pediatric pulmonary artery hypertension. Pedlatr Clin North Am, 1999, 46: 331-345.
  • 4郭潇潇,田庄,刘永太,王迁,李梦涛,曾小峰,朱文玲,方全.雾化吸入伊洛前列素对肺动脉高压患者右心室功能的影响[J].中华医学杂志,2011,91(40):2832-2836. 被引量：3
  • 5McLaughlin VV, Sithon O, Badesch DB, et al. Survival with first- line bosentan in patients with primary pulmonary hypertension. Eur Respir J, 2005, 25 : 244-249.
  • 6Galie N, Ghofrani HA, Torbicki A, et al. Sildenalil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 2005, 353 : 2148-2157.
  • 7张成,何建国,卢献灵,单广良,吴炳祥,朱鲜阳,武广华,曾小峰,郭涛,柳志红,倪新海,程显声,顾晴,赵智慧,田红燕,李为民,张端珍,李梦涛,刘洪明,郭亚娟,沈节艳,张维君,刘双,周达新,鲍春德,黄石安,陈建英,伍伟峰,黄凯,李长岭,王丽华,贺蓓.口服西地那非治疗肺动脉高压的效果和安全性初步研究[J].中华医学杂志,2011,91(6):370-374. 被引量：20
  • 8Gomberg-Maifland M, Dufton C, Oudiz RJ. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol, 2011,57: 1053-1061.
  • 9Macehia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J, 2007, 153 : 1037- 1047.

二级参考文献36

  • 1Simonneau G,Galiè N,Rubin LJ,et al.Clinical classification of pulmonary hypertension.J Am Coll Cardiol,2004,43:S5-S12.
  • 2Humbert M,Sitbon O,Simonneau G.Treatment of pulmonary arterial hypertension.N Engl J Med,2004,351:1425-1436.
  • 3Kuhn KP,Byme DW,Arbogast PG,et al.Outcome in 91consecutive patients patients with pulmonary arterial hypertension receiving epoprostenol.Am J Respir Crit Care Med,2003,167:580-586.
  • 4Rubin LJ,Badesch DB,Barst RJ,et al.Bosentan therapy for pulmonary arterial hypertension.N Engl J Med,2002,346:896-903.
  • 5Kataoka M,Satoh T,Manabe T,et al.Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol.Circ J,2005,69:461-465.
  • 6Sastry BK,Narasimhan C,Reddy NK,et al.Clinical efficacy of sildenafil in primary pulmonary hypertension:a randomized,placebo-controlled,double-blind,crossover study.J Am Coll Cardiol,2004,43:1149-1153.
  • 7Galiè N,Ghofrani HA,Torbicki A,et al.Sildenafil citrate therapy for pulmonary arterial hypertension.N Engl J Med,2005,353:2148-2157.
  • 8Garg N,Sharma MK,Sinha N.Role of oral sildenafil in severe pulmonary arterial hypertension:clinical efficacy and dose response relationship.Int J Cardiol,2007,120:306-313.
  • 9Karatza AA,Bush A,Magee AG.Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension.Int J Cardiol,2005,100:267-273.
  • 10Chau EM,Fan KY,Chow WH.Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension.Int J Cardiol,2007,120:301-305.

共引文献21

同被引文献67

  • 1胡盛寿,朱晓东,郭加强,吴学军,薛淦兴.先天性心脏病合并重度肺动脉高压的临床分级再讨论──314例远期疗效的随访研究[J].中国循环杂志,1995,10(3):151-154. 被引量：36
  • 2孙波 刘文利.右心导管测定大鼠肺动脉压的实验方法[J].中国医学科学院学报,1984,6:465-465.
  • 3李雪翔,汪太平,徐岩,史学功,朱红军,程自平,许邦龙.多普勒超声心动图评价房间隔缺损封堵后右心形态及功能的变化[J].安徽医科大学学报,2007,42(4):456-458. 被引量：1
  • 4Badeseh DB, Champion HC, Sanehez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coil Cardiol, 2009, 54 : S55-S66.
  • 5Billman GE. Ambrisentan (Myogen). Curr Opin Investig Drugs, 2002, 3 : 1483-1486.
  • 6Gali6 N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 2005, 46: 529-535.
  • 7Gali~ N, Olschewski H, Oudiz 1Ll, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation, 2008, 117: 3010-3019.
  • 8Gali~ N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J, 2009, 30: 2493-2537.
  • 9Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in puhnonary arterial hypertension from the REVEAL registry. Chest, 2012, 142 : 448-456.
  • 10Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with puhnonary arterial hypertension in the modern treatment era. Chest, 2011, 140: 301-309.

引证文献7

二级引证文献31

中华医学杂志
2012年 第22期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部